Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 9/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300487 | 0.93 | ADORA3 (0.53) | MPLADORA3KDM4EMAPT | |
| SCHEMBL13328319 | 0.91 | ADORA3 (0.47) | MPLADORA3KDM4EMAPT | |
| SCHEMBL13328316 | 0.90 | ADORA3 (0.50) | MPLADORA3KDM4EMAPT | |
| SCHEMBL13364019 | 0.90 | PLTP (0.47) | MPLADORA3KDM4EMAPT | |
| SCHEMBL13328324 | 0.88 | ADORA3 (0.56) | MPLADORA3KDM4EMAPT | |
| SCHEMBL2358584 | 0.83 | ADORA3 (0.51) | MPLADORA3 | |
| SCHEMBL13328317 | 0.82 | ADORA3 (0.61) | MPLADORA3KDM4EMAPT | |
| SCHEMBL2363666 | 0.82 | ADORA3 (0.50) | ADORA3KDM4EMAPT | |
| SCHEMBL2302579 | 0.81 | ADORA3 (0.50) | MPLADORA3KDM4EMAPTCFTR | |
| SCHEMBL3315591 | 0.81 | ADORA3 (0.50) | MPLADORA3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | MPL 1091/4885ADORA3 1254/4885TRPV1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.